OBJECTIVES: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). MATERIALS AND METHODS: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. RESULTS: When compared to the low-risk tumors, high-risk TET (B2, B3, carcinomas) contained higher proportion of cancer cells expressing VEGFA, VEGFC and VEGFD (P<0.001, P<0.001, and P<0.001) growth factors, and their receptors VEGFR1 (P=0.002), VEGFR2 (P=0.013), and VEGFR3 (P=0.041). No differences were observed in terms of PDGFRβ expression. CONCLUSIONS: According to our data, it is possible to hypothesize the existence of multiple paracrine and/or autocrine loops in TET, particularly in the high-risk ones, involved in TET growth and progression. Anti-angiogenic agents, directed to inhibit these loops, are therefore to be considered as potential tools in advanced TET therapy.

Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study.

CHIARLE, Roberto;PICH, Achille;RUFFINI, Enrico;RINALDI, Mauro;
2014-01-01

Abstract

OBJECTIVES: Tumor angiogenesis is an essential and complex process necessary for the growth of all tumors which represents a potential therapeutic target. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) or their receptor tyrosine kinases have been approved by the FDA. In thymic epithelial tumors (TET), targeted therapies have been sporadically applied due to their rarity. To ascertain the presence of potential therapeutic targets, we analyzed by immunohistochemistry the expression of angiogenesis-related biomarkers in a large series of TET arranged in Tissue Micro Arrays (TMA). MATERIALS AND METHODS: We assessed by immunohistochemistry the expression of the possible molecular target of anti-angiogenic therapy, i.e. VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, in a TMA series of 200 TET collected in the framework of a multi-institutional collaborative project for Rare Diseases. RESULTS: When compared to the low-risk tumors, high-risk TET (B2, B3, carcinomas) contained higher proportion of cancer cells expressing VEGFA, VEGFC and VEGFD (P<0.001, P<0.001, and P<0.001) growth factors, and their receptors VEGFR1 (P=0.002), VEGFR2 (P=0.013), and VEGFR3 (P=0.041). No differences were observed in terms of PDGFRβ expression. CONCLUSIONS: According to our data, it is possible to hypothesize the existence of multiple paracrine and/or autocrine loops in TET, particularly in the high-risk ones, involved in TET growth and progression. Anti-angiogenic agents, directed to inhibit these loops, are therefore to be considered as potential tools in advanced TET therapy.
2014
85
191
196
http://www.sciencedirect.com/science/article/pii/S0169500214002190#
Thymoma; Thymic epithelial tumors; Biomarkers; Tissue Micro Array; Vascular endothelial growth factor; Vascular endothelial growth factor receptor
Lattanzio R;La Sorda R;Facciolo F;Sioletic S;Lauriola L;Martucci R;Gallo E;Palmieri G;Evoli A;Alessandrini G;Ruco L;Rendina EA;Truini M;Chiarle R;Barreca A;Pich A;Ascani S;Remotti D;Tunesi G;Granone P;Ratto GB;Puma F;Pescarmona E;Piantelli M;Marino M;Carlini S;Cerasoli V;Corzani F;Melis E;Filippetti M;Canalini P;Palestro G;Lalle M;Ruffini E;Ceribelli A;Rinaldi M;Thymic Epithelial Tumor Working Group
File in questo prodotto:
File Dimensione Formato  
Lung_Cancer_2014.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 560.64 kB
Formato Adobe PDF
560.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Lung Cancer 2014_Post_Print.pdf

Open Access dal 01/09/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 313.75 kB
Formato Adobe PDF
313.75 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/148347
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
social impact